公开(公告)号：US20230142803A1

公开(公告)日：2023-05-11

申请号：US18056088

申请日：2022-11-16

申请人： Celularity Inc.

发明人： Xiaokui ZHANG ,  Ivana DJURETIC ,  Lin KANG ,  Vanessa VOSKINARIAN-BERSE ,  Bhavani STOUT ,  Robert J. HARIRI ,  Wolfgang HOFGARTNER ,  James EDINGER ,  Eric LAW ,  Vladimer JANKOVIC

IPC分类号： C12N5/0783 ,  A61K35/17 ,  C12N5/078

CPC分类号： C12N5/0646 ,  A61K35/17 ,  C12N5/0634 ,  C12N2501/91 ,  C12N2501/145 ,  C12N2501/21 ,  C12N2501/26 ,  C12N2501/125 ,  C12N2501/22 ,  C12N2501/2302 ,  C12N2501/2306 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/30 ,  C12N2501/999 ,  C12N2506/03

摘要： Provided herein are methods of producing natural killer (NK) cells and/or ILC3 cells using a three-stage expansion and differentiation method with media comprising stem cell mobilizing factors. Also provided herein are methods of suppressing tumor cell proliferation using the NK cells and/or ILC3 cells and the NK cell and/or ILC3 cell populations produced by the three-stage methods described herein, as well as methods of treating individuals having cancer or a viral infection, comprising administering the NK cells and/or ILC3 cells and the NK cell and/or ILC3 cell populations produced by the three-stage methods described herein to an individual having the cancer or viral infection.

公开(公告)号：US20220000919A1

公开(公告)日：2022-01-06

申请号：US17163316

申请日：2021-01-29

申请人： Celularity Inc.

发明人： Lin KANG ,  William VAN DER TOUW ,  Vanesssa VOSKINARIAN-BERSE ,  Xuan GUO ,  Robert J. HARIRI ,  Xiaokui ZHANG ,  Catherine BALINT ,  Nassir HABBOUBI ,  Stacy HERB ,  Sharmila KOPPISETTI ,  Tanel MAHLAKOIV ,  Bhavani STOUT ,  Junhong ZHU ,  Corey CASPER ,  Shuyang HE

IPC分类号： A61K35/17 ,  C12N5/0783

摘要： Provided herein are methods of using populations of natural killer (NK) cells and/or ILC3 cells derived from a population of hematopoietic stem or progenitor cells in methods for treating a viral infection, e.g., a coronavirus infection.

公开(公告)号：US20220160787A1

公开(公告)日：2022-05-26

申请号：US17439671

申请日：2020-03-16

申请人： Celularity Inc.

发明人： QIAN YE ,  Joseph GLEASON ,  Lin KANG ,  Robert J. HARIRI ,  Shuyang HE ,  Xiaokui ZHANG ,  Valentina ROUSSEVA

IPC分类号： A61K35/50

摘要： The present invention provides an isolated non-human placenta derived stem cell, wherein the stem cell expresses CD90 or wherein the stem cell expresses CD29. The present invention also provides a composition comprising an isolated non-human placenta derived stem cell of the invention or a population of isolated non-human placenta derived stem cells of the invention, and a carrier. The present invention also provides a composition of the invention for use in the manufacture of a medicament to reduce the incidence of rejection in a patient receiving a xenotransplant form a non-human donor. The present invention provides a method of treating a subject receiving a xenotransplant or xenotransfusion comprising the step of administering to the patient an effective amount of a non-human placenta derived stem cells.

公开(公告)号：US20190093081A1

公开(公告)日：2019-03-28

申请号：US16147525

申请日：2018-09-28

申请人： CELULARITY, INC.

发明人： Lin KANG ,  Xiaokui ZHANG ,  William VAN DER TOUW ,  Robert J. HARIRI ,  Shuyang HE

IPC分类号： C12N5/0783 ,  A61P35/00 ,  A61K35/17 ,  C12N5/071

摘要： Provided provided herein are methods of treating a subject having a brain tumor, e.g., a glioblastoma by administering to the subject an effective amount of a cell population comprising human placenta-derived natural killer cells. Also provided are methods of suppressing the growth of brain tumor cells comprising contacting the glioblastoma cells with an effective amount of a cell population comprising human placenta-derived natural killer cells. Further provided are compositions comprising subject an effective amount of a cell population comprising human placenta-derived natural killer cells for use in the treatment of a brain tumor in a subject or for use in the manufacture of a medicament for treatment of a brain tumor in a subject.

公开(公告)号：US20190330592A1

公开(公告)日：2019-10-31

申请号：US16503374

申请日：2019-07-03

申请人： Celularity, Inc.

发明人： Robert J. HARIRI ,  Mohammad A. HEIDARAN ,  Stephen JASKO ,  Lin KANG ,  Eric LAW ,  Ajai PAL ,  Bhavani STOUT ,  Vanessa VOSKINARIAN-BERSE ,  Andrew ZEITLIN ,  Xiaokui ZHANG

IPC分类号： C12N5/0783 ,  A61K35/17

摘要： Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.

公开(公告)号：US20230028680A1

公开(公告)日：2023-01-26

申请号：US17309449

申请日：2019-11-29

申请人： Celularity Inc.

发明人： Robert J. HARIRI ,  Xiaokui ZHANG ,  Lin KANG ,  William VAN DER TOUW ,  Vanessa VOSKINARIAN-BERSE ,  Xuan GUO

IPC分类号： C12N5/0783 ,  C07D487/04 ,  C07D401/12

摘要： Provided herein are methods of producing natural killer (NK) cells and/or ILC3 cells using a three-stage expansion and differentiation method with media comprising stem cell mobilizing factors. Also provided herein are methods of suppressing tumor cell proliferation using the NK cells and/or ILC3 cells and the NK cell and/or ILC3 cell populations produced by the three-stage methods described herein, as well as methods of treating individuals having cancer or a viral infection, comprising administering the NK cells and/or ILC3 cells and the NK cell and/or ILC3 cell populations produced by the three-stage methods described herein to an individual having the cancer or viral infection.

公开(公告)号：US20200330516A1

公开(公告)日：2020-10-22

申请号：US16876979

申请日：2020-05-18

申请人： Celularity Inc.

发明人： Brian MURPHY ,  Vanessa VOSKINARIAN-BERSE ,  Andrea NORDBERG ,  Keith WILSON ,  Lin KANG

IPC分类号： A61K35/17 ,  C12N5/0783 ,  A61K35/50 ,  A61K35/51 ,  C07D473/00

摘要： Provided herein are methods of producing natural killer (NK) cells using a three-stage expansion and differentiation method with media comprising stem cell mobilizing factors. Also provided herein are methods of suppressing tumor cell proliferation using the NK cells and the NK cell populations produced by the three-stage methods described herein, as well as methods of treating individuals having cancer or a viral infection, comprising administering the NK cells and the NK cell populations produced by the three-stage methods described herein to an individual having the cancer or viral infection.

公开(公告)号：US20200246393A1

公开(公告)日：2020-08-06

申请号：US16649133

申请日：2018-09-27

申请人： CELULARITY, INC.

发明人： Xiaokui ZHANG ,  Lin KANG ,  Robert J. HARIRI

IPC分类号： A61K35/50 ,  A61K35/17 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  C12N5/0783 ,  C12N5/071 ,  A61K31/454 ,  A61P35/00

摘要： Provided herein are methods of suppressing the growth or proliferation of tumor cells and methods of treating individuals having tumor cells using placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer (PINK) cells, combined natural killer (NK) cells, or combinations thereof, in combination with an antibody (e.g., anti-disialoganglioside (anti-GD2) antibody). Also provided herein are compositions comprising placental perfusate, placental perfusate cells, PINK cells, combined NK cells, or combinations thereof, in combination with an antibody (e.g., anti-GD2 antibody).

公开(公告)号：US20190153389A1

公开(公告)日：2019-05-23

申请号：US16099676

申请日：2017-05-05

申请人： CELULARITY, INC.

发明人： Steven A. FFISCHKOFF ,  Uri HERZBERG ,  Lin KANG ,  Brian MURPHY ,  Andrea NORDBERG ,  Vanessa VOSKINARIAN-BERSE ,  Keith WILSON ,  Xiaokui ZHANG ,  Han MYINT ,  Mohamed HUSSEIN

IPC分类号： C12N5/0783 ,  A61P35/02 ,  A61K35/17 ,  A61K38/20 ,  A61P35/00

摘要： Provided herein are methods of treating acute myeloid leukemia (AML) and multiple myeloma (MM) by administering an effective amount of a cell population comprising natural killer cells, wherein the cell population comprising natural killer cells is produced by a three-stage method comprising culturing a population of hematopoietic stem or progenitor cells in media comprising stem cell mobilizing factors, e.g., three-stage methods of producing NK cells in media comprising stem cell mobilizing factors starting with hematopoietic stem or progenitor cells from cells of the placenta, for example, from placental perfusate (e.g., human placental perfusate) or other tissues, for example, umbilical cord blood or peripheral blood. Further provided herein are methods of using the NK cells produced by the three-stage methods provided herein to suppress the proliferation of acute myeloid leukemia cells. In certain embodiments, the NK cells produced by the three-stage methods described herein are used in combination with IL-2.